Literature DB >> 34815691

Transcription Factor Signatures May Predict the Prognosis and Status of the Immune Microenvironment of Primary Lower-Grade Gliomas.

Peidong Liu1, Ruojie Wu1, Jinhao Zhang1, Yiming Zhang1, Chen Zhang1, Lei Chen1, Shengping Yu1, Xuejun Yang1.   

Abstract

AIM: Transcription factor (TF) in glioma, including proliferation, invasion/migration, and tumor microenvironment, has been receiving increasing attention. However, there are still no systematical analyses based on global TF. Herein, using global TF target gene sets, we comprehensively investigated their relationship with prognosis and potential biological effect in lower-grade glioma (LGG). We aimed to develop a less-biased prognostic model and provide new insight for personalized management of this disease.
METHODS: TF target gene sets were collected from MSigDB and GRID database followed by ssGSEA calculating normalized enrichment score. Comprehensive survival analysis was combined with Kaplan-Meier and Cox algorithms. Consensus cluster and lasso regression were performed to develop prognostic signatures with validation of ROC and independent external cohort. Approaches of xCell/CIBERSORT/TIMER were involved in analyzing the immune microenvironment. We also correlated identified prognostic signatures with tumor mutational burden (TMB) and m6A genes.
RESULTS: Fourteen TFs were significantly screened based on survival. Patients were classified into 2 prognosis-related clusters based on 14-TFs features. The function of differentially expressed TF target genes between Cluster1/2 was enriched mostly on glioma invasion/migration. The prognostic model was trained by 6 out of 14-TFs followed by generating risk-score as an independent prognostic indicator. We found differences between the high/low-risk group in TMB and the immune microenvironment, where the high-risk group represented "hot-tumor". Besides, 6-TFs were correlated with m6A regulation genes.
CONCLUSION: Our findings suggested that the 6-TFs model could be used to predict prognosis and predict the status of the immune microenvironment in LGG.
© 2021 Liu et al.

Entities:  

Keywords:  lower-grade glioma; prognostic model; risk signature; transcription factor target gene set; tumor immune microenvironment

Year:  2021        PMID: 34815691      PMCID: PMC8605870          DOI: 10.2147/IJGM.S335399

Source DB:  PubMed          Journal:  Int J Gen Med        ISSN: 1178-7074


  18 in total

1.  MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.

Authors:  Radhika Mathur; Yalan Zhang; Matthew R Grimmer; Chibo Hong; Michael Zhang; Saumya Bollam; Kevin Petrecca; Jennifer Clarke; Mitchel S Berger; Joanna J Phillips; Nancy Ann Oberheim-Bush; Annette M Molinaro; Susan M Chang; Joseph F Costello
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

2.  Deubiquitination and Stabilization of PD-L1 by CSN5.

Authors:  Seung-Oe Lim; Chia-Wei Li; Weiya Xia; Jong-Ho Cha; Li-Chuan Chan; Yun Wu; Shih-Shin Chang; Wan-Chi Lin; Jung-Mao Hsu; Yi-Hsin Hsu; Taewan Kim; Wei-Chao Chang; Jennifer L Hsu; Hirohito Yamaguchi; Qingqing Ding; Yan Wang; Yi Yang; Chung-Hsuan Chen; Aysegul A Sahin; Dihua Yu; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Cancer Cell       Date:  2016-11-17       Impact factor: 31.743

Review 3.  The definition of primary and secondary glioblastoma.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  Clin Cancer Res       Date:  2012-12-03       Impact factor: 12.531

4.  Glioma-associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1.

Authors:  Frank Szulzewsky; Andreas Pelz; Xi Feng; Michael Synowitz; Darko Markovic; Thomas Langmann; Inge R Holtman; Xi Wang; Bart J L Eggen; Hendrikus W G M Boddeke; Dolores Hambardzumyan; Susanne A Wolf; Helmut Kettenmann
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

5.  High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors.

Authors:  Saman Maleki Vareki
Journal:  J Immunother Cancer       Date:  2018-12-27       Impact factor: 13.751

6.  Molecular profiling of the tumor microenvironment in glioblastoma patients: correlation of microglia/macrophage polarization state with metalloprotease expression profiles and survival.

Authors:  Marko Gjorgjevski; Ricarda Hannen; Barbara Carl; Yu Li; Emilie Landmann; Malte Buchholz; Jörg W Bartsch; Christopher Nimsky
Journal:  Biosci Rep       Date:  2019-06-20       Impact factor: 3.840

7.  GTRD: an integrated view of transcription regulation.

Authors:  Semyon Kolmykov; Ivan Yevshin; Mikhail Kulyashov; Ruslan Sharipov; Yury Kondrakhin; Vsevolod J Makeev; Ivan V Kulakovskiy; Alexander Kel; Fedor Kolpakov
Journal:  Nucleic Acids Res       Date:  2021-01-08       Impact factor: 16.971

8.  The transcriptional regulator ADNP links the BAF (SWI/SNF) complexes with autism.

Authors:  Geert Vandeweyer; Céline Helsmoortel; Anke Van Dijck; Anneke T Vulto-van Silfhout; Bradley P Coe; Raphael Bernier; Jennifer Gerdts; Liesbeth Rooms; Jenneke van den Ende; Madhura Bakshi; Meredith Wilson; Ann Nordgren; Laura G Hendon; Omar A Abdulrahman; Corrado Romano; Bert B A de Vries; Tjitske Kleefstra; Evan E Eichler; Nathalie Van der Aa; R Frank Kooy
Journal:  Am J Med Genet C Semin Med Genet       Date:  2014-08-28       Impact factor: 3.908

9.  Notch1 signaling pathway promotes invasion, self-renewal and growth of glioma initiating cells via modulating chemokine system CXCL12/CXCR4.

Authors:  Li Yi; Xingchen Zhou; Tao Li; Peidong Liu; Long Hai; Luqing Tong; Haiwen Ma; Zhennan Tao; Yang Xie; Chen Zhang; Shengping Yu; Xuejun Yang
Journal:  J Exp Clin Cancer Res       Date:  2019-08-05

10.  Molecular characterization and clinical relevance of m6A regulators across 33 cancer types.

Authors:  Yongsheng Li; Jun Xiao; Jing Bai; Yi Tian; Yinwei Qu; Xiang Chen; Qi Wang; Xinhui Li; Yunpeng Zhang; Juan Xu
Journal:  Mol Cancer       Date:  2019-09-14       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.